Regulation of Bone Sialoprotein mRNA by Steroid Hormones

Åke Oldberg, Bodil Jirskog-Hed, Sara Axelsson, and Dick Heinegård

Department of Medical and Physiological Chemistry, University of Lund, S-221 00 Lund, Sweden

Abstract. In this report we demonstrate an increase in the steady-state level of bone sialoprotein (BSP) mRNA in rat calvaria and a rat osteosarcoma cell line (ROS 17/2.8) after treatment with the synthetic glucocorticoid, dexamethasone. In contrast, 1,25-dihydroxyvitamin D₃ reduced the amount of BSP mRNA in calvaria and inhibited the dexamethasone induction in ROS 17/2.8 cells. The increase in BSP mRNA is most likely due to an increase in the transcriptional rate. The stability of mRNA was unchanged after dexamethasone treatment with a half-life of ~5 h. Nuclear transcription experiments with nuclei isolated from ROS 17/2.8 cells showed an increased BSP mRNA synthesis in cells treated with dexamethasone.

Bone sialoprotein (BSP),¹ which we previously called sialoprotein II, is an acidic glycoprotein associated with the mineral matrix in bone and teeth (2, 3). The protein contains ~50% carbohydrate of which 15% is sialic acid (3). Furthermore, some 30% of the serine residues are phosphorylated and contribute to the acidity of BSP. The amino acid sequence of BSP, deduced from eDNA, predicts a 34-kD protein core with predominantly glutamic acid and glycine residues, which constitute one third of all amino acid residues (10). The protein contains several clusters of up to 10 consecutive glutamic acid residues. These negatively charged domains, together with the sialic acid residues and phosphate groups, are presumably responsible for the strong interaction with hydroxyapatite.

BSP promotes the attachment and spreading of rat osteosarcoma cells (ROS 17/12.8) as well as primary bovine chondrocytes in cell-binding experiments using plastic dishes coated with the protein (11, 12). This cell binding is apparently mediated by an RGD-containing region in BSP, which is homologous to the cell-binding domain in vitronectin (10). The BSP receptor is an integrin indistinguishable from the vitronectin receptor on the surface of ROS 17/2.8 cells (11).

BSP shares some structural features with another bone protein, osteopontin (OPN) (9). The OPN sequence contains a stretch of nine consecutive aspartic acid residues comparable to the glutamic acid clusters in BSP. OPN also contains a cell-binding RGD sequence which promotes attachment of cells in a similar way as BSP (9). The synthesis of OPN in bone cells is regulated by steroid hormones. It has been shown that 1,25-dihydroxyvitamin D₃ (vit D₃) increases the level of OPN mRNA, whereas the synthetic glucocorticoid, dexamethasone, reduces the steady-state level of OPN mRNA (15).

It is well established that steroid hormones have pronounced influence on the metabolism of bone. Some of these effects may be exerted via effects on cells, possibly mediated via cell-binding proteins. The present study, therefore, was undertaken to determine the effects of different steroid hormones on the biosynthesis of two major cell-binding bone proteins.

Materials and Methods

Cell and Tissue Cultures

Calvaria tissue was dissected from neonatal (3-4-d-old) rats. Isolated calvaria and the rat osteosarcoma cell line ROS 17/2.8 (6), respectively, were cultured in Ham's F12 medium (Gibco Laboratories, Grand Island, NY) supplemented with 10% FCS. Dexamethasone (Sigma Chemical Co., St. Louis, MO) and vit D₃ (a gift from Sandoz, A. G., Basel) were added to culture media supplemented with 2% FCS. Both steroids were used at 10⁻⁶ M in all experiments. 5,6-Dichloro-1-β-ribofuranosyl benzimidazole (DRB) (Sigma Chemical Co., St. Louis, MO), a potent inhibitor of RNA polymerase II (16), was used at a concentration of 10⁻⁴ M.

Isolation and Analysis of RNA

RNA was isolated by extraction with guanidine isothiocyanate and centrifugation in a cesium chloride gradient (7). Electrophoresis and transfer of RNA to nitrocellulose were performed as previously described (9). The filters were hybridized with an OPN cDNA probe as described (9). The BSP cDNA probe represented a 446-bp Eco RI-Pvu II fragment (nucleotide 1-446 in reference 10). Filters were hybridized with the BSP probe at 47°C in a hybridization solution containing 50% formamide (9). The filters were washed with 2 × SSC (1 × SSC is 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0) at room temperature for 1 h and finally in 0.2 × SSC at 68°C for 1 h.

In Vitro Transcription Analysis

Nuclei were isolated from ROS 17/2.8 cells (3a) and transcribed in vitro (5) using the modifications described by Jäck and Wahl (4). ³²P-labeled RNA (2 × 10⁶ cpm/ml) was hybridized to nitrocellulose filters carrying single-stranded BSP or OPN cDNA. An Eco RI-Pvu II fragment (nucleotide 1-446 in reference 10) was ligated to M13 mp18 and mp19 in sense and antisense orientation. Also an Eco RI fragment of λROP (9) was ligated to M13 in both orientations. Single-stranded M13 DNA was isolated and bound to nitrocellulose using a slot blot apparatus (Schleicher & Schuell, Inc., Keene, NH), 200 µg/well. The filters were hybridized with ³²P-

© The Rockefeller University Press. 0021-9525/89/12/3183/4 $2.00
The Journal of Cell Biology, Volume 109 (No. 6, Pt. 1), Dec. 1989 3183-3186 3183
Results

We determined the effects of dexamethasone and vit D₃ on the steady-state levels of BSP mRNA in cultured neonatal rat calvaria and in the rat osteosarcoma cell line ROS 17/2.8 (Fig. 1). BSP mRNA levels increased threefold in calvaria tissue after exposure to dexamethasone for 24 h. In contrast, treatment with vit D₃ reduced the amount to one third of that in control without steroid. Similar effects of the steroids were seen in ROS 17/2.8 cells. Without dexamethasone or with vit D₃ no BSP mRNA was detected. Dexamethasone increased the amounts of BSP mRNA to detectable levels in cultured osteosarcoma cells. In control experiments an identical set of filters were hybridized with an OPN cDNA probe. Vit D₃ increased the steady-state level of OPN mRNA about fivefold in both calvaria and ROS 17/2.8 cells. This agrees with previous results reported by Yoon et al. (15). These authors also observed a reduction in OPN mRNA after treatment with dexamethasone. In the present set of experiments, however, we did not observe significantly decreased amounts of OPN mRNA after dexamethasone treatment. This may be due to a shorter dexamethasone exposure time of 24 h used by us as compared with 72 h used by Yoon et al. The amount of BSP mRNA increased with time in dexamethasone-stimulated ROS 17/2.8 cells (Fig. 2), although the amount of BSP mRNA fluctuated with time in some experiments. The amounts of BSP mRNA were, however, always above the amount in untreated cells. The reason for this variation in BSP mRNA levels is unknown. No BSP mRNA was detected when dexamethasone and vit D₃ were added simultaneously to the osteosarcoma cells. Apparently, the vit D₃ suppression of the BSP mRNA steady-state level overrides the stimulatory effect of dexamethasone (Fig. 2).

To determine if the increase of BSP mRNA was due to an increased stability and half-life of mRNA we studied its degradation in calvaria tissue cultures (Fig. 3). Calvaria were kept in culture medium with or without dexamethasone for 24 h. After addition of DRB, a potent inhibitor of RNA synthesis (16), the rate of decreasing BSP mRNA was determined. The half-life of BSP mRNA was found to be 4–5 h and was not affected by added dexamethasone. This result indicated that the regulation of BSP mRNA by dexamethasone is at the transcriptional level. A corresponding half-life of 6 h was determined when the same filter was hybridized with the OPN cDNA probe (data not shown).

To provide further support for the assumption that the dexamethasone regulation is at the transcriptional level, we determined the amount of BSP mRNA synthesized by ROS 17/2.8 cells with or without dexamethasone in the culture medium (Fig. 4). Radiolabeled RNA was synthesized in vitro in isolated nuclei and hybridized to filters carrying the single-stranded M13 vector with BSP or OPN cDNA, in sense or antisense orientation. Labeled RNA from nuclei of dexamethasone exposed cells hybridized to single-stranded
Figure 3. Degradation of BSP mRNA in calvaria. Calvaria were cultured in medium with (○) or without (●) 10 nM dexamethasone for 24 h. DRB was added to a final concentration of 100 nM. RNA was isolated after 5 and 10 h and subjected to transfer blot analysis with BSP cDNA as a probe. The amount of BSP mRNA before addition of DRB was set to 100%. The blots used for densitometric scanning are shown inserted.

Discussion

The physiological significance of glucocorticoids in bone homeostasis is unclear but the long-term therapeutic effect on patients is a decrease in bone mass. In model systems of in vitro bone formation, however, dexamethasone has been demonstrated to promote the formation of calcified bone nodules by primary cells isolated from rat calvaria (1). This has been proposed to be due to a stimulatory effect of dexamethasone on the maturation of determined osteoprogenitor cells. It has also been suggested that the decrease in bone

BSP cDNA in the antisense but not in the sense orientation. No hybridization with BSP was seen with RNA from untreated nuclei. The control indicates that similar amounts of OPN mRNA were synthesized with and without dexamethasone. This nuclear run on experiment shows that dexamethasone increases the transcriptional rate of BSP mRNA. A separate experiment was set up with ROS 17/2.8 cells to study the role of active protein synthesis in the increased transcription of BSP mRNA upon dexamethasone treatment. Thus, cycloheximide when added simultaneously with the steroid abolished its effect on the BSP mRNA synthesis (Fig. 5).

Figure 4. Nuclear transcription assay of nuclei isolated from ROS 17/2.8 cells cultured without (A) or with (B) 10 nM dexamethasone for 24 h. 32P-labeled RNA transcribed in vitro was hybridized with nitrocellulose filters carrying single-stranded M13 vector with BSP or OPN cDNA in antisense (−) or sense (+) orientation.

Figure 5. Effect of cycloheximide on the induction of BSP mRNA by dexamethasone. ROS 17/2.8 cells were cultured for 10 h in medium (lane 1) without additive, (lane 2) containing 10 nM dexamethasone, (lane 3) containing 5 × 10^{-5} M cycloheximide, or (lane 4) containing 10 nM dexamethasone plus 5 × 10^{-5} M cycloheximide. Total RNA was isolated from the cells and 15 μg was analyzed in transfer blot analysis with BSP (top) or OPN (bottom) as probes.
mass observed after long-term use of glucocorticoids in therapy follows from a depletion of the reserves of preosteoblasts and consequently a decrease in the number of bone-mineral-producing osteoblasts (13). In this context it is relevant to note that the ROS 17/2.8 cell line attains a more osteoblastic phenotype in the presence of dexamethasone (14). The glucocorticoid causes the osteosarcoma cells to increase their expression of alkaline phosphatase, a key enzyme in the formation of hydroxypatite. Interestingly, the ROS 17/2.8 cells when cultured with dexamethasone grow to a lower density and are morphologically different from cells in the absence of dexamethasone (14). The more adherent and flattened morphology induced by the corticosteroid may be a result of increased synthesis of BSP, which promotes attachment and spreading of ROS 17/2.8 cells.

The exact mechanism of dexamethasone action on the transcription of BSP mRNA is unclear. The comparatively long time needed to reach maximum levels of BSP mRNA in ROS 17/2.8 cells indicates that it does not involve the classical binding to enhancer elements in the BSP gene of the glucocorticoid hormone–glucocorticoid receptor complex. Furthermore, we have observed that the increase in BSP mRNA requires active protein synthesis, since cycloheximide prevented the effect. No change in the morphology of the cells was observed during the incubation period, indicating that the abolished dexamethasone effect was not due to acute toxicity of cycloheximide. Cycloheximide treatment gave some reduction of the expression of OPN mRNA, probably a result of the decreasing number of viable cells during the experiment. The loss of expression of BSP mRNA during these conditions, however, indicates a more pronounced effect on the expression of this protein. Thus, the effect of dexamethasone on the steady-state level of BSP mRNA is most likely indirect and may involve changes in the phenotype of the osteosarcoma cells. A corresponding effect on bone tissue, e.g., calvaria, could involve maturation of preosteoblasts. In support, the synthesis of BSP mRNA in both calvaria and ROS 17/2.8 cells was inhibited by vit D3, which has been proposed to inhibit the maturation of osteoblasts from progenitor cells (Ishida, H., D. G. Bellows, J. E. Aubin, and J. N. M. Heersche, Calcif. Tissue Int., Suppl. 42, Abstr. 19). This effect is also in accordance with the induced mobilization of calcium into the circulation by vit D3.

The effects of steroids on the synthesis of BSP mRNA suggest that the protein is a product of mature osteoblasts producing bone matrix. The function of the protein is unknown but it may be associated with key functions of bone-producing cells, such as regulation of hydroxypatite crystal nucleation and growth.

We are grateful to Mrs. Andrea Kontos for skillful technical assistance. This work was supported by grants from the Swedish Medical Research Council, Folksamstiftelsen, Genentech, Konung Gustaf V:s 80-årsfond, Kock’s stiftelse, Österlunds stiftelse, and the medical faculty, University of Lund.

Received for publication 17 April 1989 and in revised form 3 August 1989.

References

1. Bellows, C. G., J. E. Aubin, H. N. M. Heersche, and M. E. Antosz. 1986. Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif. Tissue Int. 38:143–154.
2. Fisher, L. W., G. R. Hawkins, N. Tuross, and J. D. Termine. 1987. Isolation and partial characterization of small proteoglycans 1 and 2, bone sialoproteins I and II, and osteonectin from mineral compartment of developing bone. J. Biol. Chem. 262:9702–9708.
3. Franzen, A., and D. Heinegard. 1985. Isolation and characterization of two sialoproteins only present in bone calcified matrix. Biochem. J. 232:715–724.
4. Greenberg, M. E., and E. B. Ziff. 1984. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature (Lond.) 311:433–437.
5. Jack, H. M., and M. Wahl. 1988. Immunoglobulin mRNA stability varies during B lymphocyte differentiation. EMBO (Eur. Mol. Biol. Organ.) J. 7:1041–1046.
6. Linial, M. N. Gunderson, and M. Groudine. 1985. Enhanced transcription of c-myc in bursal lymphoma cells requires continuous protein synthesis. Science (Wash. DC). 230:1126–1132.
7. Majeska, R. J., S. B. Rodan, and G. A. Rodan. 1980. Parathyroid hormone responsive clonal cells from rat osteosarcoma. Endocrinology. 107:1494–1503.
8. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 545 pp.
9. Oldberg, A., A. Franzen, and D. Heinegard. 1986. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an ARG-GLY-ASP cell-binding sequence. Proc. Natl. Acad. Sci. USA. 83:8819–8823.
10. Oldberg, A., A. Franzen, and D. Heinegard. 1988. The primary structure of a cell-binding bone sialoprotein. J. Biol. Chem. 263:19430–19432.
11. Oldberg, Å., A. Franzen, D. Heinegard, M. Pierschbacher, and E. Ruoslahti. 1988. Identification of a bone sialoprotein receptor in osteosarcoma cells. J. Biol. Chem. 263:19433–19435.
12. Sommarin, Y., T. Larsson, and D. Heinegard. 1989. Chondrocyte-matrix interactions: Attachment to proteins isolated from cartilage. Exp. Cell Res. 184:181–192.
13. Tenebaum, H. C., and N. M. Heersche. 1985. Dexamethasone stimulates osteogenesis in chick periosteum in vitro. Endocrinology. 117:2211–2217.
14. Wires, K. M., and G. A. Rodan. 1985. Dissociation between the effects of glucocorticoids on cell spreading and phenotypic expression. In The Chemistry and Biology of Mineralized Tissues. W. T. Butler, editor. Elseco, Media Inc., Birmingham, AL. 320–325.
15. Yoon, K., R. Buenaga, and G. A. Rodan. 1987. Tissue specificity and developmental expression of rat osteopontin. Biochem. Biophys. Res. Commun. 148:1129–1136.
16. Zandomeni, R. D., Bunick, S. Ackerman, B. Mittelman, and R. Weisman. 1983. Mechanism of action of DB: effects of specific in vitro initiation of transcription. J. Mol. Biol. 167:561–575.